Education
About Us
Working with TipRanks
Follow Us
AbCellera Biologics (ABCL)
NASDAQ:ABCL
ABCL Stock Chart & Stats
$5.77
-$0.28(-8.54%)
At close: 4:00 PM EST
$5.77
-$0.28(-8.54%)
Day’s Range― - ―
52-Week Range$1.89 - $6.52
Previous CloseN/A
Volume1.71M
Average Volume (3M)5.84M
Market Cap
$1.69B
Enterprise Value$587.89M
Total Cash (Recent Filing)$553.08M
Total Debt (Recent Filing)$142.08M
Price to Earnings (P/E)―
Beta1.51
Next Earnings
Nov 06, 2025EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding298,832,920
10 Day Avg. Volume4,594,560
30 Day Avg. Volume5,843,039
Financial Highlights & Ratios
PEG Ratio-0.68
Price to Book (P/B)0.82
Price to Sales (P/S)29.91
P/FCF Ratio-4.61
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue17.88
Enterprise Value/Gross Profit-9.51
Enterprise Value/Ebitda-3.58
Forecast
1Y Price Target
$7.25Price Target Upside25.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Bulls Say, Bears Say
Bulls Say
Clinical ProgressABCL reported earnings and provided a pipeline update including the first patient dosed in Phase 1 trials for two of its programs, indicating progress in their clinical development.
Clinical TrialsAbCellera began dosing the first participants in a Phase 1 study for its ABCL635 for the potential treatment of moderate-to-severe vasomotor symptoms associated with menopause after recently receiving regulatory authorization.
Pipeline ExpansionThe Company also started discovery on an additional five partner-initiated programs with downstream economics to reach over 102 cumulative programs, up from 93 last year.
Bears Say
Clinical RiskThere is a clinical risk for targeting NK3R with ABCL635 due to concerns about sufficient target engagement and potential safety issues related to liver toxicity.
Revenue Strategy ShiftThe Company is decreasing its revenue-generating development partnership activities and focusing more on its internal pipeline development.
AbCellera Biologics News
ABCL FAQ
What was AbCellera Biologics’s price range in the past 12 months?
AbCellera Biologics lowest stock price was $1.89 and its highest was $6.51 in the past 12 months.
What is AbCellera Biologics’s market cap?
AbCellera Biologics’s market cap is $1.69B.
When is AbCellera Biologics’s upcoming earnings report date?
AbCellera Biologics’s upcoming earnings report date is Nov 06, 2025 which is in 9 days.
How were AbCellera Biologics’s earnings last quarter?
AbCellera Biologics released its earnings results on Aug 07, 2025. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.134 by $0.014.
Is AbCellera Biologics overvalued?
According to Wall Street analysts AbCellera Biologics’s price is currently Undervalued.
Does AbCellera Biologics pay dividends?
AbCellera Biologics does not currently pay dividends.
What is AbCellera Biologics’s EPS estimate?
AbCellera Biologics’s EPS estimate is -0.14.
How many shares outstanding does AbCellera Biologics have?
AbCellera Biologics has 298,832,920 shares outstanding.
What happened to AbCellera Biologics’s price movement after its last earnings report?
AbCellera Biologics reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.134. Following the earnings report the stock price went up 0.236%.
Which hedge fund is a major shareholder of AbCellera Biologics?
Currently, no hedge funds are holding shares in ABCL
AbCellera Biologics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.25 (25.65% Upside)
$7.25 (25.65% Upside)
Blogger Sentiment
Bullish
ABCL Sentiment 66%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 544.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.6%
Last 30 Days ▲ 16.6%
Last 30 Days ▲ 16.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.62%
12-Months-Change
Fundamentals
Return on Equity
-15.64%
Trailing 12-Months
Asset Growth
-0.74%
Trailing 12-Months
Company Description
AbCellera Biologics
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
ABCL Company Deck
ABCL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in clinical trials and a strong financial position, with increased revenue and continued pipeline expansion. However, the company also reported a net loss, though slightly improved from the previous year, and a decrease in R&D expenses.View all ABCL earnings summariesABCL Revenue Breakdown
93.51% Research fees
3.94% Royalty revenue
2.55% Milestone payments
ABCL Stock 12 Month Forecast
Average Price Target
$7.25
▲(25.65% Upside)
Technical Analysis
Syndax Pharmaceuticals
―
Arcus Biosciences
―
Dianthus Therapeutics
―
Edgewise Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
Ownership Overview
38.43% Insiders
4.82% Mutual Funds
<0.01% Other Institutional Investors
55.51% Public Companies and Individual Investors